trending Market Intelligence /marketintelligence/en/news-insights/trending/NWLFWltOFc63T-_nqVFbKg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Alexion, Affibody to co-develop therapy for autoimmune diseases

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Alexion, Affibody to co-develop therapy for autoimmune diseases

Alexion Pharmaceuticals Inc. and Affibody AB are jointly developing ABY-039 to treat rare Immunoglobulin G-mediated autoimmune diseases.

Affibody will receive $25 million up front from Boston-based Alexion. Affibody could also receive up to an additional $625 million upon achieving certain development and sales milestones as well as tiered low double-digit royalties.

Immunoglobulin G is the most common type of antibody found in blood circulation. ABY-039 is a bivalent antibody-mimetic — artificial peptides that behave like antibodies — that targets the neonatal Fc receptor, also called the Brambell receptor, a human protein encoded by the FCGRT gene.

ABY-039 was specifically designed to combine Affibody's protein therapeutics platform and Albumod technology to achieve an extended half-life compared to other similar therapies and potential for less frequent, self-administered therapy.

Solna, Sweden-based Affibody, a biotechnology company, has the option to co-promote ABY-039 in the U.S. and will lead its clinical development for an undisclosed indication.

The transaction is expected to close in the second quarter, subject to clearance under the Hart-Scott Rodino Act.